Research and Markets: Gram-Positive Bacterial Infections - 2015 Pipeline Insights
Gram-Positive Bacterial Infections - Pipeline Insights provides the in-depth analysis of the pipeline assets across the Gram-Positive Bacterial Infections. The main objective of this report to track competitor pipeline molecules, related research ...
Business Wire (press release) - Thu, 16 Jul 2015 05:33



What Are Bacteria?
Gram-positive bacteria stain purple because their cell walls are rich in peptidoglycan. On the other hand, Gram-negative bacteria whose cells walls have two layers take on a red coloring. The outer layer of lipids does not bind strongly to crystal ...
Live Science - Wed, 22 Jul 2015 23:33

Escherichia Coli Infections Review Reports for H1 2015 on Therapeutic Pipeline ...
Small Molecules for Bacterial Infections, Small Molecules for Escherichia Coli Infections,Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections, Small Molecules to Inhibit 23S Ribosomal RNA for Infections, Small ...
PR Newswire (press release) - Wed, 29 Jul 2015 11:22

Clinicians Are Increasingly Left with Few or even No Treatment Options
In Europe alone, over 60 SMEs explore antibacterial approaches in a broad range of bacterial infections. The programs focus on Gram-negative and Gram-positive infections, as well as pathogen-specific conditions caused by Clostridium difficile ...
Genetic Engineering & Biotechnology News - Thu, 30 Jul 2015 12:30

AmpliPhi to Present Research on Efficacy of a Novel Bacteriophage Cocktail in ...
... of a Bacteriophage Cocktail in a Staphylococcus aureus Mouse Pneumonia Model is Comparable to Vancomycin' (F-274) as part of the poster session 'New Agents and Approaches Addressing Gram-Positive Pathogens, including Mycobacteria' on Friday ...
Business Wire (press release) - Thu, 30 Jul 2015 13:03



AmpliPhi Biosciences - Calling Captain Kirk: The CSO Has Left The Enterprise ...
Vancomycin, which is now off-patent and available in generic form, accounts for 73% of sales of drugs that combat gram-positive bacterial infections (see p. 12 of Cubist (NASDAQ:CBSTZ) 2010 Annual Report), while Cubist estimated its CUBICIN daptomycin ...
Seeking Alpha - Wed, 29 Jul 2015 11:22

Oragenics up 26% on antibiotic efficacy data (OGEN)
... class of rare antibiotic compounds with a novel mechanism of action that have the potential to overcome antibiotic-resistant infections. MU1140 is active against Gram positive bacteria, including those responsible for many of healthcare-associated ...
Seeking Alpha - Wed, 29 Jul 2015 08:22



Theravance Biopharma's VIBATIV Approved in Canada for Treatment of Adults With ...
VIBATIVĀ® has also been currently permitted in Canada for therapy of individuals with complicated skin and skin structure infections (cSSSI) caused by susceptible strains of Gram-positive bacteria. VIBATIV is an injectable, once a day, lipoglycopeptide ...
Lung Disease News - Fri, 24 Jul 2015 09:36

Health Canada approves Theravance's Vibativ for HAP/VAP caused by gram ...
Pharmaceutical Business Review - Thu, 23 Jul 2015 23:46


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014